Cinepazet maleate | 50679-07-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cinepazet maleate
• 英文别名: (Z)-but-2-enedioic acid;ethyl 2-[4-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]piperazin-1-yl]acetate
• CAS: 50679-07-7
• 化学式: C24H32N2O10
• 分子量: 508.5
• InChiKey: URWISVHSKBDRKE-GVTSEVKNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.14
• 重原子数：
  36
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  152
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Process of Preparing Guanylate Cyclase C Agonists
  申请人：Bai Juncai

  公开号：US20140155575A1

  公开（公告）日：2014-06-05

  The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

  该发明提供了制备包括从本文所述的SEQ ID NOs：1-249中选择的GCC激动剂序列的肽的过程。
• DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS
  申请人：Talley John

  公开号：US20090186834A1

  公开（公告）日：2009-07-23

  Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described.

  本文描述了各种吡咯烷、咪唑啉和噁唑烷衍生物，以及含有这些化合物的药物组合物和使用这些化合物治疗疾病的方法。还描述了其他实施方式。
• ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME
  申请人：SYNERGY PHARMACEUTICALS, INC.

  公开号：US20160145307A1

  公开（公告）日：2016-05-26

  The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

  本发明提供了一种从本文描述的SEQ ID NOs:1-251所选的包含GCC激动剂序列的肽的纯化过程。该过程包括在冷冻干燥（冻干）步骤之前进行溶剂交换步骤。
• Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
  申请人：Schering Corporation

  公开号：EP1541175A2

  公开（公告）日：2005-06-15

  The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor and (b) at least one cardiovascular agent different from the sterol absorption inhibitor, which can be useful for treating vascular conditions, obesity, diabetes and lowering plasma levels of sterols.

  本发明提供的组合物、治疗组合物和方法包括：(a) 至少一种固醇吸收抑制剂和 (b) 至少一种不同于固醇吸收抑制剂的心血管药剂，它们可用于治疗血管疾病、肥胖症、糖尿病和降低血浆中的固醇水平。
• Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
  申请人：Synergy Pharmaceuticals Inc.

  公开号：EP2527360A2

  公开（公告）日：2012-11-28

  The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

  本发明提供了新型鸟苷酸环化酶-C激动剂肽及其在治疗人类疾病（包括胃肠道疾病、炎症或癌症（如胃肠道癌症））中的用途。这些肽既可单独施用，也可与 cGMP 依赖性磷酸二酯酶抑制剂联合施用。胃肠道疾病可分为肠易激综合征、便秘或胃酸过多等。胃肠道疾病可分为炎症性肠病或其他胃肠道疾病，包括克罗恩病、溃疡性结肠炎和癌症。